Admitere 2024

Domeniul doctorat Medicină
Facultatea de Medicină și Farmacie

1. Infectiile oportuniste asociate SIDA in contextul terapiei antivirale actuale    
2. Particularitati regionale ale rezistentei la antibiotice in infectiile comunitare
3. Infectia COVID-19 din perspectiva medicinei personalizate

1. Terapia antiinfectioasa: antibiotice, antiviralele, antiparazitare. 
2. Pneumoniile acute comunitare și nosocomiale. Gripa.
3. Meningitele și encefalitele acute
4. Infecțiile materno-fetale. 
5. Hepatitele virale acute și cronice. 
6. Infecția cu HIV / SIDA. 
7. Infecția cu SARS-CoV-2.
8. Rezistenta la antibiotice in infectii asociate asistentei medicale si infectii comunitare.
9. Diagnosticul infectiilor
10. Vaccinurile si bolile vaccinabile.

1. Kumar si Clark Medicină clinică/ Adam Feather, David Randall, Mona Waterhouse; coo(d. ed. în lb. română: Leonard Azamfirei, Anca Dana Buzoianu, Dan Ionuţ Gheonea, Bucureşti, 2021, Editura Hipocrate, ISBN 978-606-95178-0-2
2. Dennis Kasper, Anthony Fauci. Harrison's Infectious Diseases: Third edition, 2017, McGraw Hill Education, ISBN-13: 978125983571.
3. Centrul National de Supraveghere si Control al Bolilor Transmisibile. Metodologii. Ghiduri, protocoale si proceduri. https://www.cnscbt.ro/

1. Infuenta infectiei SARS_Cov2, asupra decesului ante-partum al fatului.
2. Importanta examinarii gravidelor la 35-37 sapt si descoperirea anomaliilor fetale tardive in sarcina
3. Strategia optima de diagnostic si tratament a HTA si Pre-eclampsiei in sarcina.

• 1.1. Wong SF, Chow KM, Leung TN, Ng WF, Ng TK, Shek CC, Ng PC, Lam PWY, Ho LC, To WWK, Lai ST, Yan, WW, Tan PYH. Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome. Am J Obstet Gynecol2004; 191: 292– 297.
• 1.2. Li AM, Ng PC. Severe acute respiratory syndrome (SARS) in neonates and children. Arch Dis Child Fetal Neonatal Ed2005; 90: 461– 465.
• 1.3. Lam CM, Wong SF, Leung TN, Chow KM, Yu WC, Wong TY, Lai ST, Ho LC. A case‐controlled study comparing clinical course and outcomes of pregnant and non‐pregnant women with severe acute respiratory syndrome. BJOG2004; 111: 771– 774.
• 2.1. Ciobanu A, Wright A, Panaitescu A, Syngelaki A, Wright D, Nicolaides KH. Prediction of imminent preeclampsia at 35–37 weeks' gestation. Am J Obstet Gynecol2019; 220: 584.e1– 11.
• 2.2. Andrietti S, Silva M, Wright A, Wright D, Nicolaides KH. Competing‐risks model in screening for pre‐eclampsia by maternal factors and biomarkers at 35–37 weeks' gestation. Ultrasound Obstet Gynecol2016; 48: 72– 79.
• 2.3. Akolekar R, Ciobanu A, Zingler E, Syngelaki A, Nicolaides KH. Routine assessment of cerebroplacental ratio at 35–37 weeks' gestation in the prediction of adverse perinatal outcome. Am J Obstet Gynecol2019; 221: 65.e1– 18.
• 3.1. ER, Tunc¸alp O, Vogel JP, Khan DN, Oladapo OT, Long Q, G¨ulmezogluAM. Implementation of effective practices in health facilities: a systematic review ofcluster randomised trials. BMJ Glob Health 2017;
• 3.2. Zwart JJ, Richter JM, Ory F, de Vries JI, Bloemenkamp KW, van Roosmalen J. Severe maternal morbidity during pregnancy, delivery and puerperium in the Netherlands:a nationwide population based study of 371 000 pregnancies. BJOG 2008; 115:842–850.
• 3.3. van ’t Hooft J, Alfirevic Z, Asztalos EV, Biggio JR, Dugoff L, Hoffman M, Lee G,Mol BW, Pacagnella RC, Pajkrt E, Saade GR, Shennan AH, Vayssi`ere C, Khan KS.CROWN initiative and preterm birth prevention: researchers and editors commit toimplement core outcome sets. BJOG 2018; 125: 8–11.

1. Metode noninvazive de evaluarea a statusului volemic la pacientul critic cu soc septic din Terapie Intensiva.
2. Caracteristicele pacientului cu trombembolia pulmonara şi infectie SARS-COV2 în comparaţie cu pacientul non-COVID-19
3. Modificarile pre- si post-operatorii ale presiunii pulmonare, monitorizate echografic transtoracic, la pacientul lobectomizat
4. Relatia dintre frecventa cardiaca si umplerea volemica cuantificata ecocardiografic

1. Trombembolia pulmonara – caracteristice la pacientul COVID-19 si non-COVID -19
2. Hipertensiunea pulmonara
3. Echilibrul hidroelectolitic si acidobazic
4. Ecocardiogafia – principii
5. Modificarile hemodinamice la pacientul de Terapie Intensiva
6. Sepsisul si socul septic.

1. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 11th Edition. 2018
2. Feigenbaum's Echocardiography. Ed. Wolters Kluwer Health. 2019
3. Jean-Louis Vincent; Edward Abraham; Freederick A.Moore; Patrick M. Kichanek; Mitchell P. Fink. Textbook of Critical Care 7th Ed. 2016
4. Richard S. Irwin; Craig M. Lilly; James M. Rippe. Manual of Intensive Care Medicine 6th Ed. 2013
5. Marino’s The ICU Book. Paul L. Marino 4th Ed. 2014
6. Recommendations for Cardiac ChamberQuantification by chocardiography in Adults:An Update from the American Societyof Echocardiography and the European Associationof Cardiovascular Imaging 2015
7. The American Society Of Echocardiography Recommendations Forcardiacchamber Quantificationin Adults: A Quick Reference Guidefrom The Ase Workflow And Lab Management Task Force 2018
8. ESC Clinical Practice Guidelines. Availabe on: https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines

1. Identificarea biofilmului polimicrobian in piciorul diabetic

1. Piciorul diabetic

1. Internal Clinical Guidelines team. Diabetic Foot Problems: Prevention and Management. (2015).
2. Centre for Clinical Practice at NICE (UK). Diabetic Foot Problems: Inpatient Management of Diabetic Foot Problems. (2011).

1. Modificari patologice la nivel cutaneo-mucos - impact asupra calitătii vietii, abordare globală,metode terapeutice si modalităti de preventie activă.
2. Evaluarea relatiei privind tratamentul cortizonic,antiinflamator,biologic administrat in dermatite si alte patologii extracutanate inclusiv osteo articulare
3. Manifestari dermatologice in diverse conditii medico chirurgicale

1. Interrelatii la nivel cutaneo sistemic cu expresie predominant la nivel facial
2. Leziunile cutanate în sindroamele de overlap ale colagenozelor majore
3. Comorbiditati in afectiuni dermatologice

• 1.1. Jones, A.L., The influence of shape and colour cue  on facial health perception, Evolution and Human Behavior (2017), https://doi.org/10.1016/j.evolhumbehav.2017.09.005
• 1.2. Henderson AJ, Holzleitner IJ, Talamas SN, Perrett DI. 2016 Perception of health from facial cues. Phil. Trans. R. Soc. B 371: 20150380. http://dx.doi.org/10.1098/rstb.2015.0380
• 1.3. Gupta MA, Gilchrest BA. Psychosocial aspects of aging skin. Dermatologic Clinics 2005;4:643-648. doi: 10.1016/j.det.2005.05.012. 
• 1.4. Fink B, Matts PJ, D’Emiliano D, et al. Colour homogeneity and visual perception of age, health and attractiveness of male facial skin. J Eur AcadDermatol Venereol. 2012;26(12):1486–1492.
• 1.5. Chronic sun damage and the perception of age, health and attractiveness, Paul J. Matts, and Bernhard Fink, DOI: 10.1039/b9pp00166b, Photochemical & Photobiological Sciences Photochem. Photobiol. Sci., 2010, 9, 421–431
• 1.6. Skin care Bootcamp: The Evolving Role of Skin care. Katie Rodan, Kathy Fields, George Majewski; Timothy Falla, Plast Reconstr Surg Glob Open 2016;4:e1152; doi:10.1097/ GOX.0000000000001152;
• 1.7. Flament F, Bazin R, Laquieze S, et al. Effect of the sun on visible clinical signs of aging in Caucasian skin. Clin Cosmet Investig Dermatol. 2013;6:221–232. 
• 1.8. Facial skin pores: a multiethnic study. Frederic Flament, Ghislain Francois, Huixia Qiu, Chengda Ye, Tomoo Hanaya, Dominique Batisse, Suzy Cointereau-Chardon, Mirela Donato, Gianeti Seixas, Susi Elaine Dal Belo, Roland Bazin, Clinical, Cosmetic and Investigational Dermatology 2015:8 85–93
• 1.9. Messaraa C, Metois A, Walsh M,et al. Antera 3D capabilities for pore measurements. Skin Res Technol. 2018;00:1–8. https://doi.org/10.1111/srt.12472
• 1.10. Lee SJ, Seok J, Jeong SY, Park KY, Li K, Seo SJ. Facial Pores: Definition, Causes, and Treatment Options. Dermatol Surg. 2016 Mar;42(3):277-85. doi: 10.1097/DSS.0000000000000657.
• 2.1. AdultsWith Eczema May Have Elevated Fracture Risk . Ricki Lewis, PhD. December 24, 2014
• 2.2. Association between eczema and increased fracture and bone or joint injury in adults: a US population-based study. .Garg N¹, Silverberg JI².JAMA Dermatol. 2015 Jan;151(1):33-41. doi: 10.1001/jamadermatol.2014.2098.
• 2.3. Van Velsen SG, Haeck IM, Knol MJ, Lam MG, Bruijnzeel-Koomen CA. Two-year assessment of effect of topical corticosteroids on bone mineral density in adults with moderate to severe atopic dermatitis. J Am Acad Dermatol. 2012;66(4):691-693.PubMedGoogle ScholarCrossref
• 2.4. Self-Reported Fracture in Dermatitis Herpetiformis Compared to Coeliac Disease Camilla Pasternack 1 , EriikaMansikka 1,2, KatriKaukinen 1,3, KaisaHervonen 1,2 , TimoReunala 1,2, Pekka Collin 4 , HeiniHuhtala 5 ID , Ville M. Mattila 6 andTeeaSalmi 1,2,* Received: 15 February 2018; Accepted: 12 March 2018; Published: 14 March 2018
• 2.5. Osteoporosis in adult patients with atopic dermatitis: A nation wide population-based studyChing-Ying Wu,^#1,2 Ying-Yi Lu,^#2,3,4 Chun-Ching Lu,⁵ Yu-Feng Su,^6,7 Tai-Hsin Tsai,^6,7 and Chieh-Hsin Wu^2,6,7,* PLoSOne. 2017; 12(2): e0171667.Published online 2017 Feb 16. doi: 10.1371/journal.pone.0171667
• 2.6. Adwan, M. H. (2015). Eular textbook on rheumatic diseases. Saudi Medical Journal, 36(12), 1503.
• 2.7. M. E. Weinblatt, M.D. (Ed.), Hochberg: Rheumatology, 7th (2018). Elsevier.
• 2.8. Ionescu, R. (2006). Esentialul in reumatologie. Editura medicala Amaltea, Bucuresti.
• 3.1. Mital Patel, MD - Dermatologic Manifestations of Gastrointestinal Disease – Medscape Link : https://emedicine.medscape.com/article/1093801-overview
• 3.2. Irwin Braverman - Skin Signs of Gastrointestinal Disease , GASTROENTEROLOGY 2003; 124:1595–1614; doi:10.1016/S0016-5085(03)00327-5
• 3.3. Maral Rahva, Justin Kerstetter- Cutaneous manifestation of gastrointestinal disease - J Gastrointest Oncol. 2016 Apr; 7(Suppl 1): S44–S54
• 3.4. Thrash B, Patel M, Shah KR - Cutaneous manifestations of gastrointestinal disease: part II - J Am Acad Dermatol. 2013 Feb;68(2):211.e1-33; quiz 244-6
• 3.5. Jonathan S. Levine - Extraintestinal Manifestations of Inflammatory Bowel Disease - Gastroenterol Hepatol (N Y). 2011 Apr; 7(4): 235–241
• 3.6. Ghid Practic de Dermatologie Oxford/Susan Burge,Rubeta Matin,Dinny Wallis;ed.versiunii in lb.romana:Calin Giurcaneanu,Florica Sandru,Alin Codrut Nicolescu.-Bucuresti:Editura Hipocrate,2020.ISBN 978-606-94576-8-9.Editia a doua.

1. Sănătatea orală în contextul patologiei sistemice
2. Tulburări ale procesului de formare și erupție dentară
3. Biomaterialele utilizate în medicina dentară

• 1.1. Noi biomarkeri și tehnici de investigare avansate pentru evaluarea secreției salivare în diverse contexte clinice
• 1.2. Managementul interdisciplinar al pacienților cu afecțiuni oro-dentare
• 1.3. Patologia orală în corelație cu diverse afecțiuni sistemice
• 2.1. Studii privind evaluarea factorilor de corelații în contextul general și modificările de structură ale dinților
• 2.2. Optimizarea diagnosticului și a procedeelor terapeutice în tulburările de formare și dezvoltare stomatognată
• 2.3. Strategii inovative în managementul tulburărilor dentare
• 3.1. Cercetări privind terapia restaurativă utilizată în stomatologie
• 3.2 Influența materialelor de restaurare dentară – terapii novatoare
• 3.3 Studii privind proprietățile materialelor utilizate în medicina dentară în diferite patologii.

1. Martha H. Wells Arthur J. Nowak, John R. Christensen, Tad R. Mabry, Janice Alisa Townsend . Pediatric Dentistry – infancy through adolescence. Ed. Saunders, septembrie, 2018.
2. Jeffrey A. Dean Dentistry for the Child and Adolescent. Ed. Mosby, aprilie 2021.
3. Cameron A., Widmer R. - Handbook of pediatric dentistry, 2nd edition. Ed. Mosby, 2003.
4. Lakshman Samaranayake. Essential Microbiology for Dentistry. Ed. Elsevier, 2018.
5. George A. Freedman. Contemporary Esthetic Dentistry, 1st Edition. Ed. Mosby, 2012.
6. Barry K. B. Berkovitz & Bernard J. Moxham & Roger W. A. Linden & Alastair J. Sloan. Master Dentistry Volume 3 Oral Biology, 1st Edition. Ed. Churchill Livingstone, 2010
7. SAUNDERS and Kimberly G. Bastin. Dental Materials, 1st Edition. Ed. Saunders, 2015.

1. Analiza comparativa la nivel local, national, international, a unor patologii infectioase cu impact asupra starii de sanatate a populatiei.
2. Analiza comparativa la nivel local, national, international, a sistemelor de supraveghere epidemiologica in unele boli transmisibile cu risc major de transmitere in populatie.
3. Impactul vaccinarii asupra curbelor de morbiditate in unele boli infectioase prevenibile prin vaccinare.

1. Analiza de morbiditate în bolile transmisibile
2. Sisteme de supraveghere în bolile transmisibile
3. Boli prevenibile prin vaccinare

1. Gordis Leon, Epidemiology, Elsevier Saunders, Fifth Edition
2. Stanley A. Plotkin, Walter A. Orestein, Paul A. Offit, Kathryn M. Edwards, Plotkin’s Vaccines, 7th Edition, booksmedicos.org
3. Centres for Disease Control and Prevention (CDC), Office of Workforce and Career Development, Atlanta, GA, Self Study Course SS1978, Principles of Epidemiology in Public Health Practice, 3rd Edition, An Introduction to Applied Epidemiology and Biostatistics, Oct. 2006, Updated May 2012 U.S. Department of Health and Human Services
4. Centrul National de Supraveghere si Control al Bolilor Transmisibile Bucuresti, Metodologii, Legislatie, Ghiduri Protocoale, Proceduri, Rapoarte anuale, Analiza date, Rapoarte OMS
5. Ivan Aurel, Tratat de Epidemiologie a bolilor transmisibile, Ed. Polirom, 2002

1. Impactul afecțiunii COVID-19 la pacientul vârstnic
2. Biomarkeri in Boala Alzheimer si strategiile terapeutice in imunosenescența
3. Particularități clinico-terapeutice in osteoporoza senila

1. Beers, Mark H.; Berkow, Robert (2000). The Merck Manual of Geriatrics (3rd ed.). Whitehouse Station, N.J.: Merck Research Laboratories. ISBN 978-0911910889.
2. Kane RL, Ouslander JG, Resnick B, Malone ML. Essentials of Clinical Geriatrics, 8th ed. New York, NY: McGraw-Hill; 2018
3. Ward KT, Reuben DB. Comprehensive geriatric assessment. UpToDate. October 19, 2018. Retrieved October 25, 2019
4. Reuben DB, Rosen S, Shickedanz HB. Chapter 10: Principles of Geriatric Assessment. In: Halter JB, Ouslander JG, Studenski S, High KP, Asthana S, Supiano MA, Ritchie C, eds. Hazzard’s Geriatric Medicine and Gerontology, 7th ed. New York, NY: McGraw-Hill Education;2017
5. Ouslander JG, Reyes B. Chapter 464: Clinical problems associated with the aging process. In: Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J, eds. Harrison’s Principles of Internal Medicine, 20th ed. New York, NY: McGraw-Hill Education;2018.
6. Zetterberg, H., Bendlin, B.B. Biomarkers for Alzheimer’s disease—preparing for a new era of disease-modifying therapies. Mol Psychiatry 26, 296–308 (2021). https://doi.org/10.1038/s41380-020-0721-9
7. DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer’s disease. Mol Neurodegener. 2019;14:32.
8. Palmqvist S, Insel PS, Stomrud E, Janelidze S, Zetterberg H, Brix B, et al. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer’s disease. EMBO Mol Med. 2019;11:e11170
9. Hemmy LS, Linskens EJ, Silverman PC, Miller MA, Talley KMC, Taylor BC, Ouellette JM, Greer NL, Wilt TJ, Butler M, Fink HA. Brief Cognitive Tests for Distinguishing Clinical Alzheimer-Type Dementia From Mild Cognitive Impairment or Normal Cognition in Older Adults With Suspected Cognitive Impairment. Ann Intern Med. 2020 May 19;172(10):678-687. doi: 10.7326/M19-3889. Epub 2020 Apr 28. PMID: 32340040.
10. Ellis G, Gardner M, Tsiachristas A, Langhorne P, Burke O, Harwood RH, Conroy SP, Kircher T, Somme D, Saltvedt I, Wald H, O'Neill D, Robinson D, Shepperd S. Comprehensive geriatric assessment for older adults admitted to hospital. Cochrane Database Syst Rev. 2017 Sep 12;9(9):CD006211. doi: 10.1002/14651858.CD006211.pub3.
11. Huang LK, Chao SP, Hu CJ. Clinical trials of new drugs for Alzheimer disease. J Biomed Sci. 2020;27:18
12. Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer’s disease drug development pipeline: 2019. Alzheimers Dement. 2019;5:272–93.
13. Bittar A, Bhatt N, Kayed R. Advances and considerations in AD tau-targeted immunotherapy. Neurobiol Dis. 2020;134:104707.
14. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med. 2016;8:595–608
15. Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, et al. High-precision plasma beta-amyloid 42/40 predicts current and future brain amyloidosis. Neurology. 2019;93:e1647–59.
16. Palmqvist S, Janelidze S, Stomrud E, Zetterberg H, Karl J, Zink K, et al. Performance of fully automated plasma assays as screening tests for Alzheimer disease-related beta-amyloid status. JAMA Neurol. 2019;76:1060–9
17. Frisoni GB, Fox NC, Jack CR Jr., Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol. 2010;6:67–77.
18. Vogt NM, Hunt JF, Adluru N, Dean DC, Johnson SC, Asthana S, et al. Cortical microstructural alterations in mild cognitive impairment and Alzheimer’s disease dementia. Cereb Cortex. 2019. https://doi.org/10.1093/cercor/bhz286. [Online ahead of print].
19. Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14:577–89.
20. Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019;90:870–81.
21. Bridel C, van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE, and the NFLG, et al. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. JAMA Neurol. 2019;76:1035–48.
22. Shen XN, Niu LD, Wang YJ, Cao XP, Liu Q, Tan L, et al. Inflammatory markers in Alzheimer’s disease and mild cognitive impairment: a meta-analysis and systematic review of 170 studies. J Neurol Neurosurg Psychiatry. 2019;90:590–8.
23. Robinson JL, Lee EB, Xie SX, Rennert L, Suh E, Bredenberg C, et al. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain. 2018;141:2181–93.
24. Brookmeyer R, Abdalla N. Estimation of lifetime risks of Alzheimer’s disease dementia using biomarkers for preclinical disease. Alzheimers Dement. 2018;14:981–8.
25. Elobeid A, Libard S, Leino M, Popova SN, Alafuzoff I. Altered proteins in the aging brain. J Neuropathol Exp Neurol. 2016;75:316–25.
26. Mattsson N, Rosen E, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology. 2012;78: 468–76
27. World Health Organization. Coronavirus Disease (COVID-2019) Situation Reports (World Health Organization, 2020).
28. Wang, C., Wang, Z., Wang, G. et al. COVID-19 in early 2021: current status and looking forward. Sig Transduct Target Ther 6, 114 (2021). https://doi.org/10.1038/s41392-021-00527-1
29. Varchetta, S., Mele, D., Oliviero, B. et al. Unique immunological profile in patients with COVID-19. Cell Mol Immunol 18, 604–612 (2021). https://doi.org/10.1038/s41423-020-00557-9
30. Sulli A, Gotelli E, Casabella A, Paolino S, Pizzorni C, Alessandri E, Grosso M, Ferone D, Smith V, Cutolo M. Vitamin D and Lung Outcomes in Elderly COVID-19 Patients. Nutrients. 2021; 13(3):717. https://doi.org/10.3390/nu13030717
31. Cascella M, Rajnik M, Aleem A, et al. Features, Evaluation, and Treatment of Coronavirus (COVID-19) [Updated 2021 Apr 20]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554776/ 
32. Bajaj V, Gadi N, Spihlman AP, Wu SC, Choi CH and Moulton VR (2021) Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections? Front. Physiol. 11:571416. doi: 10.3389/fphys.2020.571416
33. S. Hagg, J. Jylhav a, Y. Wang, H. Xu, C. Metzner, M. Annetorp, S. Garcia-Ptacek, M. Khedri, A.-M. Bostrom, A. Kadir, Age, frailty, and comorbidity as prognostic factors for short-term outcomes in patients with coronavirus disease 2019 in geriatric care, J. Am. Med. Dir. Assoc. 21 (11) (2020) 1555–1559
34. J. Feehan, N. Tripodi, V. Apostolopoulos, The twilight of the immune system: The impact of immunosenescence in aging, Maturitas (2021)
35. Aiello A, Farzaneh F, Candore G, Caruso C, Davinelli S, Gambino CM, Ligotti ME, Zareian N and Accardi G (2019) Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention. Front. Immunol. 10:2247. doi: 10.3389/fimmu.2019.02247
36. Fulop, T., Larbi, A., Hirokawa, K. et al. Immunosenescence is both functional/adaptive and dysfunctional/maladaptive. Semin Immunopathol 42, 521–536 (2020). https://doi.org/10.1007/s00281-020-00818-9

1. Secvențierea genomului virusului SARS-CoV 2
2. Rezistența bacteriană a genului Enterobacter în infecțiile urinare
3. Biomarkeri în tumorile mamare
4. Diagnosticul molecular la pacienții hematologici

1. Actualități în diagnosticul infecțiilor cu SARS-CoV 2
2. Rezistența bacteriană a agenților infecțioși în urină
3. Biomarkeri în patologia oncologică
4. Tehnici din domeniul dignosticului molecular
5. Sindroame mielo-proliferative si leucemii acute

1. Kumar si Clark Medicină clinică/ Adam Feather, David Randall, Mona Waterhouse; coo (d. ed. în lb. română: Leonard Azamfirei, Anca Dana Buzoianu, Dan Ionuţ Gheonea, Bucureşti, 2021, Editura Hipocrate, ISBN 978-606-95178-0-2
2. Dennis Kasper, Anthony Fauci. Harrison's Infectious Diseases: Third edition, 2017, McGraw Hill Education, ISBN-13: 9781259835971.
3. Centrul National de Supraveghere si Control al Bolilor Transmisibile. Metodologii. Ghiduri, protocoale si proceduri. https://www.cnscbt.ro/
4. Institutul Național de Sănătate Publică, Centrul Național de Supraveghere și Control a Bolilor Transmisibile
   
5. https://www.cnscbt.ro/index.php/analiza-cazuri-confirmate-covid19/1721-raport-saptamanal-episaptamana18
6. Kathryn V. Holmes – Coronaviridae and Their Replication, în Virology, Second Ed., ed. B. N. Fields, D. M. Knipe et al., Raven Press, Ltd, New York, 1990.
7. Susan R. Weiss and Sonia Navas-Martin – Coronavirus Pathogenesis and the Emerging Pathogen severe Acute Respiratory Coronavirus – MMBR, 2005, 69, 4, p. 635-664.
8. Greer J, Rodgers G, Galader B, Wintrob’s clinical Hematology, ed. 14, Walters Kluwer, 2019
9. Hoffbrand V, Moss P, Hoffbrand’s Essential Haematology, ed. 7, Wilwy Blackwell, 2016
10. Kaushansky K, Lichtman M, Prchal J, et al, Williams Hematology, ed.9, McGraw-Hill Education, 2016
11. Rodgers G, Young N, The Bethesda Handbook of Clinical Hematology, ed.4, Wolters Kluwer, 2018
12. Rodak B, Carr J, Clinical Hematology Atlas, ed. 5, Elsevier, 2017
13. Hoffbrand V, Vyas P, Campo E, et al, Color Atlas of Clinical Hematology: Molecular and Cellular Basis of Disease, ed.5, Wiley Blackwell, 2019
14. Lupu A, Vladareanu A, Coriu D Hematologie clinica, Bucuresti, Editura universitara „Carol Davila”, 2017
15. Gherasim L, Oproiu I Actualitati in medicina interna, Bucuresti, Editura medicala, 2019
16. Emadi A, Karp J, Acute Leukemia: Am Illustrated Guide to Diagnosis and Treatment, New York, Springer Publising, 2018
17. Barbu D, Mut Popescu D, Diagnostic imunofenotipoc in imagini, Editura Medicala, 2018
18. Enache C, Vladareanu A, Bumbea H, Caracterizarea epidemiologica si imunofenotipica a leucemiilor acute mieloide, Romanian Journal of Medical Practice, vol. 12, nr. 4, 2017, 234-239
19. Blackburn LM, Bender S, Brown S. Acute Leukemia: Diagnosis and Treatment. Semin Oncol Nurs. 2019 Dec;35(6):150950. doi: 10.1016/j.soncn.2019.150950. Epub 2019 Nov 20. PMID: 31757585.
20. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Löwenberg B, Bloomfield CD. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28. PMID: 27895058; PMCID: PMC5291965.
21. Estey EH. Acute myeloid leukemia: 2019 update on risk-stratification and management. Am J Hematol. 2018 Oct;93(10):1267-1291. doi: 10.1002/ajh.25214. PMID: 30328165.
22. Mukherjee S, Sekeres MA. Novel Therapies in Acute Myeloid Leukemia. Semin Oncol Nurs. 2019 Dec;35(6):150955. doi: 10.1016/j.soncn.2019.150955. Epub 2019 Nov 20. PMID: 31759818.
23. Kurtin S. Interdisciplinary Management of Acute Leukemia Across the Continuum of Care. Semin Oncol Nurs. 2019 Dec;35(6):150953. doi: 10.1016/j.soncn.2019.150953. Epub 2019 Nov 18. PMID: 31748172.
24. Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019 Jun;16(6):372-385. doi: 10.1038/s41571-019-0184-6. PMID: 30837712; PMCID: PMC8214555.
25. Garcia-Manero G, Chien KS, Montalban-Bravo G. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management. Am J Hematol. 2020 Nov;95(11):1399-1420. doi: 10.1002/ajh.25950. PMID: 32744763.
26. Ogawa S. Genetics of MDS. Blood. 2019 Mar 7;133(10):1049-1059. doi: 10.1182/blood-2018-10-844621. Epub 2019 Jan 22. PMID: 30670442; PMCID: PMC6587668.
27. Smith BN, Savona M, Komrokji RS. Challenges in Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN). Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):1-8. doi: 10.1016/j.clml.2018.11.019. Epub 2018 Nov 23. PMID: 30555034; PMCID: PMC7493410.
28. Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, Orazi A, Tefferi A. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018 Feb 9;8(2):15. doi: 10.1038/s41408-018-0054-y. PMID: 29426921; PMCID: PMC5807384.